Search

Background Lung squamous cell carcinoma (LUSC) remains a poor survival rate, calling for a novel molecular with diagnostic and treatment value. Accumulative evidence found bone morphogenetic proteins (BMPs) and their receptors (BMPRs) play important roles in tumorigenesis and progression, however, was lack of comprehensive analysis of their expression in LUSC. Methods . R/Limma package was performed to analyze the differential expression of BMPs/BMPRs in combination of TCGA and GTEx, and explore their expression characteristics with LUSC tumorigenesis in GSE33479. Meanwhile, survminer packages were performed to explore their prognostic value and correlation of clinical features in LUSC. Then, the potential diagnostic biomarkers and mechanisms associated with LUSC progression were further explored through weight gene correlation network analysis (WGCNA). At the same time, LASSO analysis was performed to construct a prognostic risk model for LUSC with the differential expression of BMPs/BMPRs as the core. Finally, the specimens were collected from 33 patients with LUSC and detected by IHC to confirm the relationship between protein levels of the above diagnostic BMPs/BMPRs and progression of LUSC. Results On the whole, 2 upregulated genes (BMP8A, BMP7) and 8 downregulated genes (BMP2, BMP5, BMP6, GDF5, GDF7, GDF10, ACVRL1 and BMPR2) were identified differentially expressed genes in LUSC. In these differentially expressed genes, GDF10 was only a significant correlation with pathological T stage of LUSC (p

Background An increasing number of original studies suggest that estrogen receptor beta (ERβ) expression may be related to non-small cell lung cancer (NSCLC) prognosis; however, the evidence remains inconclusive and conflicting. We aimed to systematically evaluate the expression and prognostic value of ERβ in NSCLC, and to explain the inconsistency between ERβ protein and mRNA level. Methods PubMed, Embase, and Web of Science databases were searched for studies (published before October 6, 2020) reporting the prognostic value of ERβ protein expression in NSCLC. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) were calculated. Transcriptome and survival data of lung adenocarcinoma patients were obtained from public databases for differential expression and survival analyses. Immunohistochemistry (IHC) was performed to examine the ERβ protein expression in 39 NSCLC patients. Western blotting and RT-qPCR were performed to analyze ERβ expression in two paired NSCLC and normal adjacent tissue samples. The effect of methyltransferase-like 13 (METTL3) on ERβ expression was investigated in a lung cancer cell line. Results Meta-analysis of 23 studies with a total of 3744 patients demonstrated that high protein expression of overall ERβ and cytoplasmic ERβ indicated poor OS (HR: 1.05, 95% CI: 1.00 to 1.10; HR: 1.48, 95% CI: 1.13 to 1.95) in NSCLC. For lung adenocarcinoma especially, high protein expression of both overall/cytoplasmic ERβ and nuclear ERβ suggested poor OS (HR: 1.54, 95% CI: 1.05 to 2.25; HR: 1.36, 95% CI: 1.03 to 1.80). Bioinformatics analysis indicated the expression of ERβ mRNA was not associated with the prognosis of lung adenocarcinoma. Analysis of public databases showed that ERβ mRNA is not highly expressed in tumor tissues, however, IHC results revealed that ERβ protein is highly expressed in NSCLC tissues. We validated this inconsistency in ERβ expression in paired tumors and normal adjacent tissues from patients. Moreover, METTL3 knockdown in the A549 cell line downregulated ERβ protein expression but not ERβ mRNA expression. Conclusions Our study elucidated the inconsistency between ERβ protein and mRNA expression levels and their prognostic values. The results indicated that METTL3-driven enhanced translation in NSCLC may cause this inconsistency.

Aim: The aim was to evaluate the efficacy and safety of chimeric antigen receptor T (CAR-T) cell in B-cell non-Hodgkin lymphoma (B-NHL). Materials & methods: A meta-analysis was conducted using eligible clinical trials, which were obtained from electronic medical literature databases. Results: A total of 24 clinical trials with 590 patients were included. The best overall response rate was 66% and complete remission rate was 46%. The incidence rates of cytokine-release syndrome and neurotoxicity (grade ≥ 3) were 9 and 5%, respectively. The various clinical factors were analyzed. Autogenic CAR-T cell may lead to improved efficacy than allogeneic CAR-T cell. CD20 CAR-T cell may show increased efficacy than CD19 CAR-T cell. Conclusion: CAR-T immunotherapy has remarkable efficacy and low toxicity in relapsed/refractory B-NHL.

Background Situs inversus totalis (SIT) is a rare congenital condition which is characterized by abnormal placement of the thoracic and abdominal organs. Laparoscopic and thoracoscopic esophagectomy with intrathoracic anastomosis is technically difficult and has rarely been reported in SIT patients with esophageal cancer. Case presentation: We report a SIT patient whose condition is complicated by middle and lower esophageal cancer. This 55-year-old patient underwent total laparoscopic and thoracoscopic esophagectomy with intrathoracic anastomosis. The overall operation time was 270 minutes. Estimated blood loss was 150 mL and the patient was discharged after 20 days. Conclusions Laparoscopic and thoracoscopic esophagectomy with intrathoracic anastomosis is technically feasible and secure in SIT patients with esophageal cancer.